Navigation Links
Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
Date:5/10/2010

el modulation and orphan G protein-coupled receptor identification and established a transcriptional profiling lab to apply leading gene expression technologies to exploratory research efforts.  Dr. Novak performed his post-doctoral training at Yale University School of Medicine in immunobiology, received his Ph.D. in biology from California Institute of Technology, and graduated magna cum laude from Amherst College in Massachusetts with a B.A. in biology and chemistry.  He is the author of more than 45 scientific abstracts and publications.

"Fate Therapeutics is the first company to singularly pursue adult stem cells as therapeutic targets of conventional drug discovery," said Dr. Novak. "I look forward to working with the unmatched team at Fate to translate the Company's unique approach to novel stem cell biology for the discovery and development of a pipeline of new medicines for a broad range of diseases and conditions."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes.  The Company's award-winning, proprietary iPSC technology platform incorporates the most advanced viral, small molecule and protein reprogramming methods and offers a highly efficient, minimally invasive system to recapitulate human physiology for commercial scale drug discovery and therapeutic use.  The Company's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.  Fate Therapeutics is currently conducting a Phase
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
2. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
3. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
4. Silence Therapeutics Appoints New Vice President of Research
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
7. invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial
8. Cornerstone Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
9. Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients
10. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
11. Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MITs Technology Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... This is a professional and in-depth study ... industry in Global and China. The report provides a ... industry chain structure. Global market analysis and Chinese domestic ... developments, trends and competitive landscape of the market. A ... offered. , The report also focuses on development policies ...
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/21/2014)... at the University of Basel in Switzerland have ... a charged molecule for the first time. These ... measurements of molecular properties and may also contribute ... technology. The results were published in the scientific ... study of the interaction between matter and light, ...
Breaking Biology Technology:m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2
... Inc. (OTC Bulletin Board: NWBO ) (NW Bio) joined ... over the course of more than 13 months, the parties ... brain cancer in Germany. As a result, the Company is ... with both its clinical trial program and Hospital Exemption cases ...
... J.D., will offer her expert perspective on  the ... she presents "EHRs: Meaningful Use & Beyond" during ... held  April 24-26, 2012, at the Thelma Keller ... During the presentation, Pita, who serves as executive ...
... facilitated the evolution and complexity of terrestrial organisms, including human ... by those organisms, which in turn were able to generate ... oxygen molecules work inside the body, more attention is being ... to thwart them. A number of environmental ...
Cached Biology Technology:Northwest Bio and Fraunhofer IZI Announce Milestones Reached 2Northwest Bio and Fraunhofer IZI Announce Milestones Reached 3Northwest Bio and Fraunhofer IZI Announce Milestones Reached 4Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Avocado Oil: The 'Olive Oil Of The Americas'? 2Avocado Oil: The 'Olive Oil Of The Americas'? 3Avocado Oil: The 'Olive Oil Of The Americas'? 4
(Date:9/22/2014)... key molecular cog in a plant,s biological clock ... based on temperature. , Transcription factors, or genetic switches, ... such as light, rain, soil quality, or even ... USC has isolated one, called FBH1, that reacts to ... needed while in keeping it on a consistent track. ...
(Date:9/22/2014)... the Society of Environmental Toxicology and Chemistry (SETAC) held ... prioritize the scientific research needed to understand the risks ... environment. The effort was extended, and results were ... international journal, Integrated Environmental Assessment and Management ... podcast interviewing the lead author of the study, Murray ...
(Date:9/22/2014)... YORK CITY (September 22, 2014)The Brain & ... the award of NARSAD Young Investigator Grants ... 200 of the world,s most promising young ... for groundbreaking neurobiological research will seek to ... strategies for psychiatric disorders that affect one ...
Breaking Biology News(10 mins):Genetic switch regulates a plant's internal clock based on temperature 2Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... new use as an adjuvant to cancer therapy, providing an ... study published in the Feb. 15 issue of Clinical Cancer ... Gallez, Ph.D., professor of pharmacy at the Université de Louvain ... A into two types of mouse tumors, the tumors' cellular ...
... H5N1 influenza samples in Southeast Asia shows not only ... are related but also that they belong to two ... for Disease Control and Prevention report their findings today ... "As the virus continues its geographic expansion, it is ...
... in Africa declared that a dramatic rise in tuberculosis (TB) ... TB case notifications have increased as much as four-fold over ... HIV. When individuals are infected with both HIV and TB, ... to active TB. , To combat the problem, the ...
Cached Biology News:Botox could help target resistant tumors for treatment 2Botox could help target resistant tumors for treatment 3Study outlines genetic differences between potential pandemic influenza strains 2
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: